Chris Chamberlain (@CAChamberlain_) profile picture

Chris Chamberlain

@CAChamberlain_

Translational research PhD student at the National Center for Cancer Immune Therapy (CCIT-DK) in Herlev, Denmark.

dk.linkedin.com/in/chrisachamberlain
Joined October 2021
  • Tweets4
  • Following30
  • Followers21
Chris Chamberlain retweeted
Marco Donia (@DoniaMarco) profile picture
Marco Donia@DoniaMarco11 Jul 2022
A 8+ years journey bringing the first results. This is great news for patients and for science. Great work of the previous and current members of the TIL teams at @CCITdk and @NKI_nl
CCIT-DK: National Center for Cancer Immune Therapy (@CCITdk) profile pictureCCIT-DK: National Center for Cancer Immune Therapy@CCITdk11 Jul 2022
Replying to @NKI_nl
@NKI_nl and @CCITdk announce TIL #celltherapy meets the primary endpoint of progression-free survival in #melanoma in a randomized phase 3 trial. Full press release at herlevhospital.dk/ccit-denma…
Image from CCIT-DK: National Center for Cancer Immune Therapy (@CCITdk)
1
3
1
19
Researchers at @HerlevGentofte reported on highly efficient PD-1-targeted #CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T #celltherapy in @moltherapy Oncolytics (#MTO). bit.ly/3GAntjP
Image from Molecular Therapy Family of Journals (@MolTherapy)
5
3
10
Big day for @CCITdk! Basic discoveries from @CCITdk developed into a clinical trial at @CCITdk. Anti-PD1 #immunotherapy plus #vaccine against IDO/PD-L1, impressive response rates. Hope for more effective treatments for patients with #Melanoma #melsm #dkforsk
Nature Medicine (@NatureMedicine) profile pictureNature Medicine
@NatureMedicine9 Dec 2021
A first-in-class immune-modulating IDO/PD-L1 targeting vaccine combined with nivolumab in a phase 1/2 trial achieved promising clinical activity and long-lasting immune responses in patients with advanced #melanoma #NMedClinical @CCITdk @uni_copenhagen nature.com/articles/s41591-0…
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab...

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab...

Nature Medicine - A first-in-class immune-modulating IDO/PD-L1-targeting vaccine combined with nivolumab in a phase 1/2 trial achieved very promising clinical activity and long-lasting immune...

nature.com
4
6
Improving #Immunotherapy monitoring, a new study from @AriannaDraghi @CAChamberlain_ and colleagues describing efficient identification of tumor-specific reactive tumor-infiltrating lymphocytes. Support by @cancer_dk @lundbeckfonden @DFF_raad @SSTSundhed @HerlevGentofte #dkforsk
Frontiers - Immunology (@FrontImmunol) profile pictureFrontiers - Immunology@FrontImmunol11 Oct 2021
New Research: Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens: Detecting the entire repertoire of tumor-specific reactive… frontiersin.org/articles/10.… #immunology
2
6
Load more